8-K: Guardian Pharmacy Services Announces Preliminary 2024 Results and Provides 2025 Guidance

Guardian Pharmacy Services reports preliminary unaudited financial results for Q4 and full year 2024, exceeding expectations and providing 2025 financial guidance.

Summary

• Guardian Pharmacy Services announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
• Revenue for Q4 2024 is expected to be approximately $338.6 million, a 20.5% increase year-over-year.
• This growth was driven by organic business growth and acquisitions of Heartland Pharmacy and Freedom Pharmacy.
• Resident count is expected to be approximately 186,000 at the end of Q4 2024, a 14.1% increase year-over-year.
• Net income for Q4 is expected to be between $10.1 million and $11.1 million, a decrease of $3.5 million to $4.5 million year-over-year, primarily due to income tax provision expense.
• Adjusted EBITDA for Q4 is expected to be approximately $25.9 million, a 30.3% increase year-over-year.
• Revenue for the full year 2024 is expected to be approximately $1.228 billion, a 17.4% increase year-over-year.
• Net loss for the full year is expected to be between ($71.8) million and ($72.8) million, a decrease of $109.5 million to $110.5 million year-over-year, primarily due to $131.5 million in share-based compensation expense related to the Corporate Reorganization and IPO.
• Adjusted EBITDA for the full year is expected to be approximately $90.8 million, a 19.2% increase year-over-year.
• For the full year 2025, Guardian provides revenue guidance of $1.330 billion to $1.350 billion and adjusted EBITDA guidance of $97.0 million to $101.0 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong growth in revenue and adjusted EBITDA, exceeding expectations for the past year and providing optimistic guidance for the future. The negative impact of share-based compensation on net income is acknowledged but framed as a one-time event related to the IPO.

Positives

• The company experienced strong organic growth and benefited from recent acquisitions.
• Revenue was positively impacted by an increase in flu and COVID-19 vaccinations administered through clinics.
• Adjusted EBITDA increased significantly year-over-year for both Q4 and the full year 2024.
• The company is providing positive revenue and adjusted EBITDA guidance for 2025.
• The company closed the acquisition of a pharmacy in Morristown, NJ in early November 2024, establishing a new MSA.

Negatives

• Net income decreased year-over-year for Q4 2024 due to income tax provision expense.
• The company reported a net loss for the full year 2024 due to significant share-based compensation expense related to the Corporate Reorganization and IPO.
• Share-based compensation expense of $131.5 million significantly impacted the net income for the year.

Risks

• The preliminary unaudited financial results are subject to the company's normal quarter and year-end accounting procedures and external audit, and are subject to adjustment.
• The company's ability to effectively execute business strategies, implement new initiatives, and improve efficiency is a risk.
• Maintaining and expanding relationships with LTCF operators on favorable terms is a risk.
• The impact of a national emergency, public health crisis, global pandemic or outbreak of infectious disease on the company's employees and business and on the supply chain and the LTCFs served is a risk.
• Continuing government and private efforts to lower pharmaceutical costs, including by limiting pharmacy reimbursements, is a risk.
• Changes in, and the company's ability to comply with, healthcare and other applicable laws, regulations or interpretations is a risk.
• The company's ability to retain members of its senior management team, local pharmacy management teams and pharmacy professionals is a risk.
• Maintaining the security and integrity of operating and information technology systems and infrastructure (e.g., against cyber-attacks) is a risk.
• Product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals dispensed is a risk.
• The sufficiency of the company's sources of liquidity and financial resources to fund future operating expenses and capital expenditure requirements, and the ability to raise additional capital, if needed, is a risk.

Future Outlook

Guardian expects revenue of $1.330 billion to $1.350 billion and adjusted EBITDA of $97.0 million to $101.0 million for the full year ending December 31, 2025.

Management Comments

• 'We're proud to report that we ended the year on a strong note, exceeding our expectations for the fourth quarter and year ended December 31, 2024,' said Fred Burke, President & CEO of Guardian.
• Fred Burke also stated that the outperformance was driven by strong organic growth, acquisitions, and the new benefit of the seasonal trend related to conducting vaccine clinics.
• Fred Burke stated that the company enters 2025 well-positioned for success and remains committed to meeting the needs of all residents served.

Industry Context

Guardian Pharmacy Services operates in the long-term care (LTC) pharmacy services market, which is experiencing growth due to the increasing elderly population and the rising need for assisted living facilities; the company is the largest LTC Pharmacy in the US in terms of ALF and memory care market share with ~12%.

Comparison to Industry Standards

• The assisted living facility (ALF) market is projected to grow by ~5% CAGR through 2030.
• The overall LTC Pharmacy Market (including SNF) is approximately ~$25B.
• The ALF and Memory Care Pharmacy Market is approximately ~$7B.
• Guardian serves approximately 186,000 residents in approximately 7,000 LTCFs across 38 states.

Stakeholder Impact

• Shareholders may be positively impacted by the revenue and adjusted EBITDA growth, as well as the positive guidance for 2025.
• Employees may be positively impacted by the company's growth and success.
• Customers (LTCFs and residents) should benefit from the company's commitment to meeting their needs and improving clinical outcomes.

Next Steps

• The company will announce complete fourth quarter and full year 2024 financial results on March 26, 2025.
• Management will hold a conference call to discuss the results on March 26, 2025, at 4:30 p.m. ET.

Key Dates